Navigation Links
Novus Scientific Announces the World's 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
Date:9/26/2011

SINGAPORE, Sept. 26, 2011 /PRNewswire/ -- Novus Scientific today announced TIGR® Matrix Surgical Mesh, the world's first and only long-term resorbable mesh, as an alternative to permanent synthetic mesh. First introduced in the US in 2010, TIGR® Matrix Surgical Mesh is currently being used in many surgical applications as an alternative to permanent synthetic mesh and expensive biologic devices.

Characteristics of TIGR® Matrix Surgical Mesh
TIGR® Matrix Surgical Mesh is knitted from two different synthetic absorbable fibers, possessing different degradation characteristics. The first fiber, making up approximately 40% of the matrix by weight, is a copolymer of glycolide, lactide, and trimethylene carbonate. The second fiber, making up approximately 60% of the matrix by weight, is a copolymer of lactide, and trimethylene carbonate. Both fibers degrade by bulk hydrolysis once implanted.

Based on the product's absorption characteristics, in vitro testing showed that the first fiber retains its functional capabilities for 1-2 weeks and in vivo studies in the abdominal wall of sheep showed that the first fiber was fully absorbed after 4 months. The same in vitro testing showed that the second fiber retains its functional capabilities for 6 months and in vivo studies in the abdominal wall of sheep indicated that the second fiber is completely absorbed after approximately 36 months.

"We at Novus Scientific have long prided ourselves on identifying clinical need and developing innovative products to address that need. We are pleased to highlight the fact that TIGR® Matrix Surgical Mesh is a viable alternative to permanent synthetic mesh on both a physiological treatment level and a budgetary level when used by physicians performing surgeries that reinforce soft tissue where weakness exists," said Thomas Engstrom, Founder and CEO of Novus Scientific.

"Surgeons want to provide the best treatment for their patients. Now, TIGR® Matrix Surgical Mesh offers surgeons an alternative to non-absorbable synthetic mesh," commented James Archetto, President of Novus Scientific, Inc.

Mark Swierzewski, MD, a urological surgeon from Tampa, FL stated, "TIGR® Matrix has been a part of my practice since 2010. It provides me and my patients with a viable alternative to non-absorbable synthetic mesh."

About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of absorbable synthetic medical devices. Visit our PRESSROOM: http://www.mynewsdesk.com/pressroom/novus-scientific

TIGR® is a trademark of Novus Scientific Pte. Ltd

CONTACT:
jim.archetto@novusscientific.com
781-577-2599


'/>"/>
SOURCE Novus Scientific
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
2. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
3. Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of SOFTISSUE - The Issue of Soft Tissue, Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
6. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
7. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
8. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
11. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):